Perfil molecular do câncer de mama triplo negativo: Uma revisão sistemática / Molecular profile of negative triple breast cancer: A systematic review

Emanuela Sinimbu Silva Rossoni, Marcela Barbosa Hércules, Julliete Cristina de Oliveira, Areta Agostinho Rodrigues de Souza, Hugo de Carlos Maciel Rossoni

Abstract


O câncer de mama é um agravo de relevância mundial por ser a primeira causa de câncer e a primeira causa de mortalidade por câncer em mulheres no Brasil e no Mundo. Dentre seus subtipos, temos o triplo-negativo que se refere aos tumores quenão expressam receptores de estrógeno, progesterona e receptor de fator de crescimento epidermal humano, HER2, quando analisados por imuno-histoquímica. O fenótipo triplo-negativo tem maior incidência em mulheres com idade inferior a 50 anos,afrodescendentese predominantemente na pré-menopausa. A grande preocupação acerca dessa neoplasiarecai sobre seu comportamento agressivo e a falta de opções terapêuticas específicascom eficácia clinicamente comprovada. Nesse cenário, o presente trabalho visa fazer um levantamento bibliográfico recente da pesquisa de marcadores celulares associados ao perfil biomolecular do câncer de mama triplo negativo afim de fornecer uma identificação mais precisa desse fenótipo e mais particularmente de seus fatores prognóstico.


Keywords


Câncer de Mama, Triplo Negativo, Saúde da Mulher, Molecular.

References


INSTITUTO NACIONAL DE CÂNCER (Brasil). Estimativa 2020. Incidência do Câncer no Brasil. Rio de Janeiro: INCA, 2019.

GOLDHIRSCH, Aron et al. Strategies for subtypes—dealingwiththediversityofbreastcancer: highlightsoftheStGallenInternationalExpertConsensus onthePrimaryTherapyofEarlyBreastCancer 2011. Annalsofoncology, v. 22, n. 8, p. 1736-1747, 2011.

BRENTON, James D. et al. Molecular classificationand molecular forecastingofbreastcancer: ready for clinicalapplication?. Journalofclinicaloncology, v. 23, n. 29, p. 7350-7360, 2005.

DENT, Rebecca et al. Triple-negative breastcancer: clinicalfeaturesandpatternsofrecurrence. Clinicalcancerresearch, v. 13, n. 15, p. 4429-4434, 2007.

MAVADDAT, Nasim et al. Pathologyofbreastandovariancancersamong BRCA1 and BRCA2 mutationcarriers: resultsfromthe Consortium ofInvestigatorsofModifiersof BRCA1/2 (CIMBA). CancerEpidemiologyandPreventionBiomarkers, v. 21, n. 1, p. 134-147, 2012.

WONG-BROWN, Michelle W. et al. Prevalenceof BRCA1 and BRCA2 germlinemutations in patientswith triple-negative breastcancer. Breastcancerresearchandtreatment, v. 150, n. 1, p. 71-80, 2015.

DING, S. L. et al. Abnormalityofthe DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breastcancerisrelatedtotumour grade. British jornal ofcancer, v. 90, n. 10, p. 1995-2001, 2004.

MARTINS, Filipe C. et al. Evolutionarypathways in BRCA1-associated breasttumors. Cancerdiscovery, v. 2, n. 6, p. 503-511, 2012.

MARTINS, Luhan Chaveiro et al. Padrão de metástase no câncer de mama triplo negativo. Ver Bras Mastologia, v. 27, n. 1, p. 8-14, 2017.

TAMIMI, Rulla M. et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast cancer research and treatment, v. 131, n. 1, p. 159-167, 2012.

PHIPPS, Amanda I. et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. Journal of the National Cancer Institute, v. 103, n. 6, p. 470-477, 2011.

BIANCHINI, Giampaolo et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature reviews Clinical Oncology, v. 13, n. 11, p. 674, 2016.

SILVA, Fátima et al. Carcinoma da mama de tipo basal. Acta MedPort, v. 21, p. 373-378, 2008.

KREIKE, Bas et al. Gene expressionprofilingandhistopathologicalcharacterizationof triple-negative/basal-like breast carcinomas. BreastCancerResearch, v. 9, n. 5, p. R65, 2007.

LEHMANN, Brian D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation, v. 121, n. 7, p. 2750-2767, 2011.

USCANGA-PERALES, Grecia Iris; SANTUARIO-FACIO, Sandra Karina; ORTIZ-LÓPEZ, Rocío. Triple negative breastcancer: Decipheringthebiologyandheterogeneity. Medicina universitaria, v. 18, n. 71, p. 105-114, 2016.

RAJ-KUMAR, Praveen-Kumar et al. PCA-PAM50 improves consistencybetweenbreast câncer intrinsicandclinicalsubtypingreclassifying a subsetof luminal A tumors as luminal B. Scientificreports, v. 9, n. 1, p. 1-13, 2019.

MOHER, David et al. Preferredreportingitems for systematic reviews and meta-analyses: the PRISMA statement. PLoSmed, v. 6, n. 7, p. e1000097, 2009.

CAZET, Aurélie S. et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nature communications, v. 9, n. 1, p. 1-18, 2018.

BUISSERET, Laurence et al. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. AnnalsofOncology, v. 29, n. 4, p. 1056-1062, 2018.

MOLINO, Annamaria et al. Ki‐67 immunostaining in 322 primarybreastcancers: associationswithclinicalandpathologicalvariablesandprognosis. Internationaljournalofcancer, v. 74, n. 4, p. 433-437, 1997.

JOVANOVIĆ, Bojana et al. A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67. ClinicalCancerResearch, v. 23, n. 15, p. 4035-4045, 2017.

SPORIKOVA, Zuzana et al. Geneticmarkers in triple-negative breastcancer. ClinicalBreastCancer, v. 18, n. 5, p. e841-e850, 2018.

ADAMS, Sylvia et al. Prognosticvalueof tumor-infiltratinglymphocytes in triple-negative breastcancersfromtwophase III randomizedadjuvantbreastcancertrials: ECOG 2197 and ECOG 1199. Journalofclinicaloncology, v. 32, n. 27, p. 2959, 2014.

SCHMIDT, Marcus et al. Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. BreastCancerResearch, v. 20, n. 1, p. 15, 2018

KAHRAMAN, Mustafa et al. MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. Scientificreports, v. 8, n. 1, p. 1-11, 2018.

TOLANEY, Sara M. et al. Phase II and biomarker study of cabozantinib in metastatic triple‐negative breast cancer patients. The oncologist, v. 22, n. 1, p. 25, 2017.

YUAN, Jupeng et al. CHST9 rs1436904 genetic variant contributes to prognosis of triple-negative breast cancer. Scientificreports, v. 7, n. 1, p. 1-8, 2017.

BONNEFOI, Hervé et al. Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. British jornal ofcancer, v. 120, n. 9, p. 913-921, 2019.

MCNAMARA, Keely May et al. Androgen receptor in triple negative breastcancer. The Journalofsteroidbiochemistryand molecular biology, v. 133, p. 66-76, 2013.

HEIN, Alexander et al. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III G epar Q uinto study. International jornal ofcancer, v. 137, n. 12, p. 2981-2988, 2015.

GRUDZINSKI, Melina et al. Expressão da cox-2 e CD105 no câncer de mama e sobrevida livre de doença.RevAssocMedBras, v. 52, n. 4, p. 275-80, 2006.

ZAGOURI, Flora et al. Protein expression patterns of cell cycle regulators in operable breast cancer. PloS one, v. 12, n. 8, p. e0180489, 2017.

GONÇALVES, Anthony et al. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget, v. 7, n. 48, p. 79428, 2016.

OLIVEIRA, M. et al. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. AnnalsofOncology, v. 30, n. 8, p. 1289-1297, 2019.

FOULDS, Gemma A. et al. Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: identification of a 3 gene signature which predicts relapse of triple negative breast cancer. Frontiers in immunology, v. 9, p. 2028, 2018.

CHOPRA, Neha et al. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nature communications, v. 11, n. 1, p. 1-12, 2020.

ZAWISTOWSKI, Jon S. et al. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. Cancer discovery, v. 7, n. 3, p. 302-321, 2017.

GOUSSIA, Anna et al. Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial. Plos one, v. 13, n. 7, p. e0200302, 2018.

WISINSKI, Kari B. et al. Targeting estrogen receptor beta in a phase 2 study of high-dose estradiol in metastatic triple-negative breast cancer: a Wisconsin Oncology Network Study. Clinicalbreastcancer, v. 16, n. 4, p. 256-261, 2016.

KIMBUNG, Siker et al. Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: results from the Phase II PROMIX trial. International jornal ofcancer, v. 142, n. 3, p. 618-628, 2018.

SCHOUTEN, Philip C. et al. BRCA1‐like profile predicts benefit of tandem high dose epirubicin‐cyclophospamide‐thiotepa in high risk breast cancer patients randomized in the WSG‐AM01 trial. InternationalJournalofCancer, v. 139, n. 4, p. 882-889, 2016.

LINDNER, J. L. et al. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Annalsofoncology, v. 26, n. 1, p. 95-100, 2015.

TANABE, Yuko et al. Pathological features of triple‐negative breast cancers that showed progressive disease during neoadjuvant chemotherapy. Cancerscience, v. 108, n. 7, p. 1520-1529, 2017.

CINTRA, Jane Rocha Duarte et al. Perfil imuno-histoquímico e variáveis clinicopatológicas no câncer de mama. Revista da Associação Médica Brasileira, v. 58, n. 2, p. 178-187, 2012.

YUAN, Yinyin. Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer. Journalof The Royal Society Interface, v. 12, n. 103, p. 20141153, 2015.




DOI: https://doi.org/10.34117/bjdv6n10-600

Refbacks

  • There are currently no refbacks.